F20 F22 F25
Conditions
Interventions
Group 1: The first arm of the study includes the intervention group, which consists of participants with a self-reported psychotic disorder (see: Disease under investigation/health problem).
The inte
Sponsors
Universitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik für Psychiatrie und Psychotherapie Forschungsbereich Neuropsychologie und Psychotherapie
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Diagnosis of schizophrenia/psychotic disorder according to self-report; sufficient competence of Turkish or German language; informed consent; presence of internet access and smartphone; willingness to participate in two anonymous online surveys; willingness to participate in the 4-week self-help smartphone app intervention; willingness to use the self-help smartphone app on their own responsibility; willingness to leave an anonymized email address for the survey.
Exclusion criteria
Exclusion criteria: Acute suicidality (measured with the PHQ-9 item 9, cut-off > 2)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| •The Rosenberg Self-Esteem Scale (RSE) will be used as the primary success parameter to assess the level of self-esteem in the last week (at T0 and T1 after 4 weeks). | — |
Secondary
| Measure | Time frame |
|---|---|
| • The reduction in psychosis symptoms measured with the Psychotic Symptom Rating Scales (PSYRATS) (difference between baseline and post). • The increase in quality of life measured with the global item of the World Health Organization Quality of Life Scale - Brief Version (difference between baseline and post after 4 weeks). • The influence of the intervention on general psychopathological symptoms measured with individual items of the Symptom Check-List Scale (SCL-90) & Generalized Anxiety Disorder Scale (GAD-7), Patient Health Questionnaire (PHQ-9) as well as cognitive insight measured with the Beck Cognitive Insight Scale (BCIS) and internalized stigmatization measured with the short version of the Internatlized Stigma of Mental Illness Inventory (ISMI-9). Further explorations • The influence of treatment expectations and treatment evaluations measured with the Patients’ Therapy Expectation and Evaluation Questionnaire (PATHEV) (only at baseline) on primary and secondary endpoints (especially on the increase in self-esteem, the reduction in psychosis symptoms and the increase in quality of life) and on the duration of adherence to the app • Subjective satisfaction with the app, measured with the "Fragebogen zur Messung der Patientenzufriedenheit" (ZUF-8) and the "Positive und Negative Auswirkungen von Psychotherapie" (PANEPS) (only at post) | — |
Countries
Austria, Germany, Switzerland, Turkey
Contacts
Public ContactEsra Cesur
Universitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik für Psychiatrie und Psychotherapie Forschungsbereich Neuropsychologie und Psychotherapie
Outcome results
None listed